

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Prescient Therapeutics Limited
<b>ABN</b>	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	James Campbell
<b>Date of last notice</b>	3 December 2014

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-
<b>Date of change</b>	23 November 2015
<b>No. of securities held prior to change</b>	Nil
<b>Class</b>	Unlisted options exercisable at \$0.085 (8.5 cents) per option on or before 4 November 2018.
<b>Number acquired</b>	200,000 unlisted options
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
<b>No. of securities held after change</b>	200,000 unlisted options

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Nature of change</b>          Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Grant of unlisted options following shareholder approval provided at the Company's 2015 Annual General Meeting held on 4 November 2015.</p>
--	--

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<p><b>No. and class of securities to which interest related prior to change</b>          Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<p><b>Value/Consideration</b>          Note: If consideration is non-cash, provide details and an estimated valuation</p>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<p><b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b></p>	No
<p><b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b></p>	N/A
<p><b>If prior written clearance was provided, on what date was this provided?</b></p>	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Prescient Therapeutics Limited
<b>ABN</b>	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Steven Engle
<b>Date of last notice</b>	3 December 2014

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-
<b>Date of change</b>	23 November 2015
<b>No. of securities held prior to change</b>	Nil
<b>Class</b>	Unlisted options exercisable at \$0.085 (8.5 cents) per option on or before 4 November 2018.
<b>Number acquired</b>	300,000 unlisted options
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
<b>No. of securities held after change</b>	300,000 unlisted options

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<p><b>Nature of change</b>          Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Grant of unlisted options following shareholder approval provided at the Company's 2015 Annual General Meeting held on 4 November 2015.</p>
--	--

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<p><b>No. and class of securities to which interest related prior to change</b>          Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<p><b>Value/Consideration</b>          Note: If consideration is non-cash, provide details and an estimated valuation</p>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<p><b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b></p>	No
<p><b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b></p>	N/A
<p><b>If prior written clearance was provided, on what date was this provided?</b></p>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Prescient Therapeutics Limited
<b>ABN</b>	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Paul Hopper
<b>Date of last notice</b>	26 June 2015

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<b>Deborah Anne Coleman</b> (a related party of Mr Hopper)  <b>Moreglade Pty Ltd</b> (a controlled entity of Mr Hopper)  <b>Kilinwata Investments Pty Ltd</b> (a controlled entity of Mr Hopper)  <b>Alexandra Jane Hopper</b> (a related party of Mr Hopper)  <b>Horatia Isabelle Hopper</b> (a related party of Mr Hopper)  <b>India Lucy Hopper</b> (a related party of Mr Hopper)  <b>Scarlett Augusta Wiseman Hopper</b> (a related party of Mr Hopper)
<b>Date of change</b>	23 November 2015

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	
<b>Paul Edward Alexander Hopper</b>	966,667 Fully paid ordinary shares
<b>Deborah Anne Coleman</b> (a related party of Mr Hopper)	2,216,667 Fully paid ordinary shares
<b>Moreglade Pty Ltd</b> (a controlled entity of Mr Hopper)	2,333,334 Fully paid ordinary shares
<b>Kilinwata Investments Pty Ltd</b> (a controlled entity of Mr Hopper)	3,388,334 Fully paid ordinary shares
<b>Alexandra Jane Hopper</b> (a related party of Mr Hopper)	33,334 Fully paid ordinary shares
<b>Horatia Isabelle Hopper</b> (a related party of Mr Hopper)	33,334 Fully paid ordinary shares
<b>India Lucy Hopper</b> (a related party of Mr Hopper)	33,334 Fully paid ordinary shares
<b>Scarlett Augusta Wiseman Hopper</b> (a related party of Mr Hopper)	33,334 Fully paid ordinary shares
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	
<b>Paul Edward Alexander Hopper</b>	71,470 Fully paid ordinary shares
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$3,859.38

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held after change</b></p> <p><b>Paul Edward Alexander Hopper</b></p> <p><b>Deborah Anne Coleman</b> (a related party of Mr Hopper)</p> <p><b>Moreglade Pty Ltd</b> (a controlled entity of Mr Hopper)</p> <p><b>Kilinwata Investments Pty Ltd</b> (a controlled entity of Mr Hopper)</p> <p><b>Alexandra Jane Hopper</b> (a related party of Mr Hopper)</p> <p><b>Horatia Isabelle Hopper</b> (a related party of Mr Hopper)</p> <p><b>India Lucy Hopper</b> (a related party of Mr Hopper)</p> <p><b>Scarlett Augusta Wiseman Hopper</b> (a related party of Mr Hopper)</p>	<p>1,038,137 Fully paid ordinary shares</p> <p>2,216,667 Fully paid ordinary shares</p> <p>2,333,334 Fully paid ordinary shares</p> <p>3,388,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p>
<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Participation in the Company's Share Purchase Plan Offer dated 29 October 2015.</p>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<p><b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.



# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Prescient Therapeutics Limited
<b>ABN</b>	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Steven Lee Yatomi-Clarke
<b>Date of last notice</b>	26 June 2015

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<b>Arrow Wealth Ltd &lt;Berbay Family A/C&gt;</b> (a controlled entity of Mr Yatomi-Clarke)  <b>Novetera Pty Ltd &lt;SAYC Super Fund A/C&gt;</b> (a controlled entity of Mr Yatomi-Clarke)  <b>Alexandra Elizabeth Yatomi-Clarke</b>
<b>Date of change</b>	23 November 2015
<b>No. of securities held prior to change</b>	2,040,000 Fully paid ordinary shares
<b>Class</b>	1. Fully paid ordinary shares 2. Unlisted options exercisable at \$0.085 (8.5 cents) per option on or before 4 November 2018.
<b>Number acquired</b>	1. 214,412 Fully paid ordinary shares 2. 200,000 unlisted options
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	1. \$11,578.29 2. Nil
<b>No. of securities held after change</b>	2,254,412 Fully paid ordinary shares 200,000 unlisted options
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1. Participation in the Company's Share Purchase Plan Offer dated 29 October 2015. 2. Grant of unlisted options following shareholder approval provided at the Company's 2015 Annual General Meeting held on 4 November 2015.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.